Memory disorders: Novel treatments, clinical perspective
- 1 January 1994
- journal article
- review article
- Published by Elsevier in Life Sciences
- Vol. 55 (25-26) , 2189-2194
- https://doi.org/10.1016/0024-3205(94)00400-5
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivoDrug Development Research, 1993
- A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study GroupJAMA, 1992
- Treatment Trial of Oxiracetam in Alzheimer's DiseaseArchives of Neurology, 1992
- Oxiracetam in dementia: a double-blind, placebo-controlled studyActa Neurologica Scandinavica, 1992
- Oxiracetam andd-pyroglutamic acid antagonize a disruption of passive avoidance behaviour induced by the N-methyl-d-aspartate receptor antagonist 2-amino-5-phosphonovaleratePsychopharmacology, 1990
- Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slicesBritish Journal of Pharmacology, 1990
- Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholinePharmacology Biochemistry and Behavior, 1987
- Experimental Behavioral Studies with Oxiracetam on Different Types of Chronic Cerebral ImpairmentClinical Neuropharmacology, 1986
- Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodentsPsychopharmacology, 1982
- Human Memory and the Cholinergic SystemArchives of Neurology, 1974